Stereotactic radiosurgery as primary and salvage treatment for brain metastases from breast cancer

Clinical article

Restricted access

Object

To evaluate the role of stereotactic radiosurgery (SRS) in the management of brain metastases from breast cancer, the authors assessed clinical outcomes and prognostic factors for survival.

Methods

The records from 350 consecutive female patients who underwent SRS for 1535 brain metastases from breast cancer were reviewed. The median patient age was 54 years (range 19–84 years), and the median number of tumors per patient was 2 (range 1–18 lesions). One hundred seventeen patients (33%) had a single metastasis to the brain, and 233 patients (67%) had multiple brain metastases. The median tumor volume was 0.7 cm3 (range 0.01–48.9 cm3), and the median total tumor volume for each patient was 4.9 cm3 (range 0.09–74.1 cm3).

Results

Overall survival after SRS was 69%, 49%, and 26% at 6, 12, and 24 months, respectively, with a median survival of 11.2 months. Factors associated with a longer survival included controlled extracranial disease, a lower recursive partitioning analysis (RPA) class, a higher Karnofsky Performance Scale score, a smaller number of brain metastases, a smaller total tumor volume per patient, the presence of deep cerebral or brainstem metastases, and HER2/neu overexpression. Sustained local tumor control was achieved in 90% of the patients. Factors associated with longer progression-free survival included a better RPA class, fewer brain metastases, a smaller total tumor volume per patient, and a higher tumor margin dose. Symptomatic adverse radiation effects occurred in 6% of patients. Overall, the condition of 82% of patients improved or remained neurologically stable.

Conclusions

Stereotactic radiosurgery was safe and effective in patients with brain metastases from breast cancer and should be considered for initial treatment.

Abbreviations used in this paper: ARE = adverse radiation effect; EORTC = European Organisation for Research and Treatment of Cancer; GKS = Gamma Knife surgery; KPS = Karnofsky Performance Scale; MST = median survival time; OS = overall survival; PFS = progression-free survival; RPA = recursive partitioning analysis; RTOP = Radiation Therapy Oncology Group; SRS = stereotactic radiosurgery; WBRT = whole-brain radiation therapy.

Article Information

* Drs. Kondziolka and Kano contributed equally to this work.

Address correspondence to: Douglas Kondziolka, M.D., Department of Neurological Surgery, University of Pittsburgh, Suite B-400, UPMC Presbyterian, 200 Lothrop Street, Pittsburgh, Pennsylvania 15213. email: kondziolkads@upmc.edu.

Please include this information when citing this paper: published online October 1, 2010; DOI: 10.3171/2010.8.JNS10461.

© AANS, except where prohibited by US copyright law.

Headings

Figures

  • View in gallery

    Kaplan-Meier plot showing OS after SRS according to RPA classification.

  • View in gallery

    Kaplan-Meier plot showing OS after SRS according to the number of brain metastases. Patients with < 5 brain metastases had significantly longer survival after radiosurgery (p = 0.049).

  • View in gallery

    Kaplan-Meier plot showing OS after SRS according to the overexpression of HER2/neu. Patients with the overexpression of HER2/neu had significantly longer survival after radiosurgery (p < 0.0005).

  • View in gallery

    Kaplan-Meier plot showing the development of distant new brain tumors after SRS in patients categorized according to the total number of brain metastases (solitary vs 2–4 vs > 5 metastases). The median time free from another tumor of solitary, 2–4, and > 5 metastases before GKS was 15.3, 11.4, and 8.8 months, respectively.

References

1

Akyurek SChang ELMahajan AHassenbusch SJAllen PKMathews LA: Stereotactic radiosurgical treatment of cerebral metastases arising from breast cancer. Am J Clin Oncol 30:3103142007

2

Amendola BEWolf ALCoy SRAmendola MBloch L: Gamma knife radiosurgery in the treatment of patients with single and multiple brain metastases from carcinoma of the breast. Cancer J 6:88922000

3

Andrews DWScott CBSperduto PWFlanders AEGaspar LESchell MC: Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 363:166516722004

4

Aoyama HShirato HTago MNakagawa KToyoda THatano K: Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 295:248324912006

5

Barnholtz-Sloan JSSloan AEDavis FGVigneau FDLai PSawaya RE: Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 22:286528722004

6

Bartsch RRottenfusser AWenzel CDieckmann KPluschnig UAltorjai G: Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer. J Neurooncol 85:3113172007

7

Boogerd WVos VWHart AABaris G: Brain metastases in breast cancer; natural history, prognostic factors and outcome. J Neurooncol 15:1651741993

8

Chang ELWefel JSHess KRAllen PKLang FFKornguth DG: Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol 10:103710442009

9

Combs SESchulz-Ertner DThilmann CEdler LDebus J: Treatment of cerebral metastases from breast cancer with stereotactic radiosurgery. Strahlenther Onkol 180:5905962004

10

Cox JDStetz JPajak TF: Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organisation for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31:134113461995

11

Dawood SBroglio KEsteva FJIbrahim NKKau SWIslam R: Defining prognosis for women with breast cancer and CNS metastases by HER2 status. Ann Oncol 19:124212482008

12

DiLuna MLKing JT JrKnisely JPChiang VL: Prognostic factors for survival after stereotactic radiosurgery vary with the number of cerebral metastases. Cancer 109:1351452007

13

DiStefano AYong Yap YHortobagyi GNBlumenschein GR: The natural history of breast cancer patients with brain metastases. Cancer 44:191319181979

14

Firlik KSKondziolka DFlickinger JCLunsford LD: Stereotactic radiosurgery for brain metastases from breast cancer. Ann Surg Oncol 7:3333382000

15

Fokstuen TWilking NRutqvist LEWolke JLiedberg ASignomklao T: Radiation therapy in the management of brain metastases from breast cancer. Breast Cancer Res Treat 62:2112162000

16

Frazier JLBatra SKapor SVellimana AGandhi RCarson KA: Stereotactic radiosurgery in the management of brain metastases: an institutional retrospective analysis of survival. Int J Radiat Oncol Biol Phys 76:148614922009

17

Fuller BGKaplan IDAdler JCox RSBagshaw MA: Stereotaxic radiosurgery for brain metastases: the importance of adjuvant whole brain irradiation. Int J Radiat Oncol Biol Phys 23:4134181992

18

Gaspar LScott CRotman MAsbell SPhillips TWasserman T: Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37:7457511997

19

Gaspar LEScott CMurray KCurran W: Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases. Int J Radiat Oncol Biol Phys 47:100110062000

20

Goyal SPrasad DHarrell F JrMatsumoto JRich TSteiner L: Gamma knife surgery for the treatment of intracranial metastases from breast cancer. J Neurosurg 103:2182232005

21

Jawahar AShaya MCampbell PAmpil FWillis BKSmith D: Role of stereotactic radiosurgery as a primary treatment option in the management of newly diagnosed multiple (3–6) intracranial metastases. Surg Neurol 64:2072122005

22

Kased NBinder DKMcDermott MWNakamura JLHuang KBerger MS: Gamma Knife radiosurgery for brain metastases from primary breast cancer. Int J Radiat Oncol Biol Phys 75:113211402009

23

Lederman GWronski MFine M: Fractionated radiosurgery for brain metastases in 43 patients with breast carcinoma. Breast Cancer Res Treat 65:1451542001

24

Lin NUBellon JRWiner EP: CNS metastases in breast cancer. J Clin Oncol 22:360836172004

25

Mahmoud-Ahmed ASSuh JHLee SYCrownover RLBarnett GH: Results of whole brain radiotherapy in patients with brain metastases from breast cancer: a retrospective study. Int J Radiat Oncol Biol Phys 54:8108172002

26

Melisko MEGlantz MRugo HS: New challenges and opportunities in the management of brain metastases in patients with ErbB2-positive metastatic breast cancer. Nat Clin Pract Oncol 6:25332009

27

Muacevic AKreth FWTonn JCWowra B: Stereotactic radiosurgery for multiple brain metastases from breast carcinoma. Cancer 100:170517112004

28

Patchell RARegine WF: The rationale for adjuvant whole brain radiation therapy with radiosurgery in the treatment of single brain metastases. Technol Cancer Res Treat 2:1111152003

29

Pirzkall ADebus JLohr FFuss MRhein BEngenhart-Cabillic R: Radiosurgery alone or in combination with whole-brain radiotherapy for brain metastases. J Clin Oncol 16:356335691998

30

Schouten LJRutten JHuveneers HATwijnstra A: Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 94:269827052002

31

Serizawa THiguchi YOno JMatsuda SNagano OIwadate Y: Gamma Knife surgery for metastatic brain tumors without prophylactic whole-brain radiotherapy: results in 1000 consecutive cases. J Neurosurg 105:Suppl86902006

32

Sneed PKLamborn KRForstner JMMcDermott MWChang SPark E: Radiosurgery for brain metastases: is whole brain radiotherapy necessary?. Int J Radiat Oncol Biol Phys 43:5495581999

33

Sneed PKSuh JHGoetsch SJSanghavi SNChappell RBuatti JM: A multi-institutional review of radiosurgery alone vs. radiosurgery with whole brain radiotherapy as the initial management of brain metastases. Int J Radiat Oncol Biol Phys 53:5195262002

34

Soffietti RRudā RMutani R: Management of brain metastases. J Neurol 249:135713692002

35

Tsukada YFouad APickren JWLane WW: Central nervous system metastasis from breast carcinoma. Autopsy study Cancer 52:234923541983

TrendMD

Metrics

Metrics

All Time Past Year Past 30 Days
Abstract Views 98 98 37
Full Text Views 145 145 9
PDF Downloads 69 69 8
EPUB Downloads 0 0 0

PubMed

Google Scholar